Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

In this phase 1-2 trial, the TK inhibitor repotrectinib led to an objective response in 79% of patients with ROS1 fusion-positive NSCLC and no previous ROS1 TK inhibitor use. Median progression-free survival was nearly 3 years.

Saved in:

Bibliographic Details
Main Authors:	Drilon, Alexander (Author) , Camidge, D. Ross (Author) , Lin, Jessica J. (Author) , Kim, Sang-We (Author) , Solomon, Benjamin J. (Author) , Dziadziuszko, Rafal (Author) , Besse, Benjamin (Author) , Goto, Koichi (Author) , Langen, Adrianus Johannes de (Author) , Wolf, Jürgen (Author) , Lee, Ki Hyeong (Author) , Popat, Sanjay (Author) , Springfeld, Christoph (Author) , Nagasaka, Misako (Author) , Felip, Enriqueta (Author) , Yang, Nong (Author) , Velcheti, Vamsidhar (Author) , Lu, Shun (Author) , Kao, Steven (Author) , Dooms, Christophe (Author) , Krebs, Matthew G. (Author) , Yao, Wenxiu (Author) , Beg, Muhammad Shaalan (Author) , Hu, Xiufeng (Author) , Moro-Sibilot, Denis (Author) , Cheema, Parneet (Author) , Stopatschinskaja, Shanna (Author) , Mehta, Minal (Author) , Trone, Denise (Author) , Graber, Armin (Author) , Sims, Gregory (Author) , Yuan, Yong (Author) , Cho, Byoung Chul (Author)
Format:	Article (Journal)
Language:	English
Published:	January 10, 2024
In:	The New England journal of medicine Year: 2024, Volume: 390, Issue: 2, Pages: 118-131
ISSN:	1533-4406
DOI:	10.1056/NEJMoa2302299
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa2302299 Verlag, lizenzpflichtig, Volltext: https://www.nejm.org/doi/full/10.1056/NEJMoa2302299
Author Notes:	Alexander Drilon, D. Ross Camidge, Jessica J. Lin, Sang-We Kim, Benjamin J. Solomon, Rafal Dziadziuszko, Benjamin Besse, Koichi Goto, Adrianus Johannes de Langen, Jürgen Wolf, Ki Hyeong Lee, Sanjay Popat, Christoph Springfeld, Misako Nagasaka, Enriqueta Felip, Nong Yang, Vamsidhar Velcheti, Shun Lu, Steven Kao, Christophe Dooms, Matthew G. Krebs, Wenxiu Yao, Muhammad Shaalan Beg, Xiufeng Hu, Denis Moro-Sibilot, Parneet Cheema, Shanna Stopatschinskaja, Minal Mehta, Denise Trone, Armin Graber, Gregory Sims, Yong Yuan, and Byoung Chul Cho for the TRIDENT-1 investigators

Description
Summary:	In this phase 1-2 trial, the TK inhibitor repotrectinib led to an objective response in 79% of patients with ROS1 fusion-positive NSCLC and no previous ROS1 TK inhibitor use. Median progression-free survival was nearly 3 years.
Item Description:	Gesehen am 29.07.2025
Physical Description:	Online Resource
ISSN:	1533-4406
DOI:	10.1056/NEJMoa2302299